develop
new
recombin
factor
viii
design
implement
answer
number
unmet
need
patient
affect
hemophilia
turoctocog
alfa
bioengin
specif
chines
hamster
ovari
clone
present
translat
posttransl
characterist
sulphat
glycosyl
biosimilar
natur
circul
form
fviii
aim
devoid
minim
chang
may
impact
immunogen
antigen
recombin
protein
produc
cell
line
media
maintain
free
anim
human
plasma
deriv
downstream
process
purif
perform
five
step
immunoaffin
chromatographi
ionexchang
chromatographi
viru
inactiv
mean
solventdeterg
treatment
nanofiltr
end
gel
filtrat
provid
best
possibl
margin
safeti
known
unknown
infecti
agent
larg
clinic
trial
seem
confirm
expect
place
turoctocog
alfa
term
high
qualiti
safeti
recombin
fviii
toward
goal
overcom
actual
futur
challeng
hemophilia
therapi
coagul
cascad
tightli
regul
effici
zymogenproteas
system
factor
viii
fviii
cofactor
amplifi
thousand
time
format
rate
stabl
clot
defici
absenc
fviii
due
mutat
chromosom
x
gene
hemophilia
predispos
repeat
spontan
induc
bleed
latter
trauma
surgeri
consequ
repeat
joint
muscl
bleed
patient
suffer
sever
debilit
musclearticular
damag
expos
lifethreaten
bleed
episod
replac
therapi
miss
factor
therefor
mainstay
treatment
patient
affect
hemophilia
replac
therapi
base
exogen
fviii
infus
time
bleed
demand
therapi
prevent
schedul
bleed
episod
prophylaxi
sinc
first
transfus
whole
blood
introduct
freezedri
clot
factor
concentr
life
expect
hemophiliac
increas
yr
nevertheless
life
expect
drop
yr
mean
age
death
yr
next
two
decad
three
quarter
hemophiliac
found
infect
hiv
hepat
b
c
virus
epidem
burden
acceler
approv
first
recombin
fviii
rfviii
product
last
yr
present
new
challeng
treatment
hemophilia
new
infecti
threat
occurr
neutral
inhibitor
exogen
fviii
rais
patient
sever
hemophilia
treat
first
time
rdna
fviii
concentr
furthermor
hemostat
protect
limit
short
halflif
exogen
fviii
intraven
administr
requir
mainten
good
venou
access
especi
children
therefor
number
possibl
improv
current
treatment
hemophilia
fviii
concentr
character
follow
properti
posttransl
structur
function
characterist
similar
natur
circul
form
fviii
devoid
rel
minor
chang
manufactur
fviii
may
impact
immunogen
puriti
risk
old
newli
emerg
infecti
agent
transmiss
furthermor
phase
iii
clinic
trial
new
fviii
concentr
longer
plasma
halflif
obtain
adequ
hemostat
protect
weekli
administr
current
go
brief
review
discuss
manufactur
process
new
third
gener
btruncat
rfviii
turoctocog
alfa
turoctocog
alfa
design
answer
actual
unmet
need
hemophilia
patient
bioengin
use
innov
technolog
appli
futur
fviii
product
manufactur
process
link
immunolog
safeti
rfviii
previou
experi
fviii
product
point
potenti
risk
develop
new
rfviii
concentr
immunogen
abil
induc
immun
respons
neoantigen
abil
bind
secret
surfac
antibodi
product
antibodi
recombin
protein
influenc
sever
factor
includ
structur
properti
protein
formul
presenc
impur
format
aggreg
larg
complex
protein
fviii
requir
critic
posttransl
addit
particularli
sulphat
glycosyl
mammalian
express
system
may
implement
chang
necessari
proper
structur
function
fviii
choic
suit
cellular
environ
provid
opportun
minim
inhibitor
incid
clinic
level
chines
hamster
ovari
cho
cell
commonli
use
mammalian
recombin
cell
clone
largescal
product
rfviii
progress
cho
cultur
technolog
brought
substanti
optim
protein
product
includ
improv
gene
express
cultur
process
medium
develop
protein
nativ
structur
turoctocog
alfa
synthes
cho
cell
show
sulphat
glycosyl
pattern
superimpos
plasmaderiv
fviii
analysi
turoctocog
alfa
degre
sulphat
demonstr
six
tyrosin
site
fviii
sulphat
everi
site
perform
peculiar
role
function
antigen
term
turoctocog
alfa
glycosyl
mainli
character
presenc
carbohydr
chain
ubiquit
human
organ
absenc
nonhuman
glycan
epitop
critic
express
differ
cultur
cell
nonhuman
epitop
carri
potenti
real
implic
inhibitori
issu
futhermor
character
sulphat
glycosyl
critic
step
assess
improv
consist
product
process
amelior
cultur
media
nonanim
sourc
ongo
import
ensur
product
consist
qualiti
without
potenti
danger
contamin
plasmaderiv
concentr
potenti
danger
contamin
concern
consist
qualiti
product
perform
reliabl
suppli
differ
compon
serum
includ
protein
peptid
hormon
enzym
electrolyt
lipid
carbohydr
vitamin
constitu
develop
serumfre
media
must
formul
cell
line
fact
even
differ
clone
cho
cell
line
may
requir
specif
cultiv
process
environ
manufactur
turoctocog
alfa
requir
humanand
animalderiv
compon
turoctocog
alfa
produc
cho
cell
grow
medium
free
plasmaderiv
ingredi
lowprotein
synthet
medium
contain
necessari
nutrient
element
filtrat
elimin
contamin
moreov
animalderiv
materi
use
product
raw
materi
employ
manufactur
process
includ
chromatographi
media
affin
ligand
filter
henc
technolog
plasma
anim
freeproduct
turoctcog
alfa
resolv
safeti
issu
pathogen
transmiss
serum
addit
serumfre
technolog
avoid
variabl
protein
lowprotein
medium
avoid
high
protein
content
exposur
element
may
contribut
reduc
immunogen
rfviii
manufactur
recombin
product
address
issu
emerg
infecti
agent
act
two
front
limit
cancel
use
human
plasma
reagent
use
cell
cultur
purif
step
stabil
storag
buffer
time
viru
inactiv
remov
measur
adopt
prepar
plasmaderiv
product
solvent
deterg
process
common
viru
inactiv
techniqu
use
process
vulner
envelop
virus
known
hepat
virus
hbv
hcv
hiv
recent
emerg
west
nile
viru
chikungunya
viru
new
influenza
strain
sever
acut
respiratori
syndrom
coronaviru
gamma
irradi
size
target
viru
wide
employ
method
inactiv
nonlipidco
virus
parvovirus
enterovirus
circovirus
howev
studi
involv
hemophiliac
treat
yr
viral
inactiv
clot
factor
concentr
identifi
seroconvers
incid
yr
antihuman
parvoviru
transmiss
agent
resist
viral
inactiv
via
solventdeterg
treatment
extent
heat
radiat
thu
necessari
implement
method
inactiv
remov
potenti
contamin
virus
includ
separationpurif
techniqu
ion
exchang
immunoaffin
chromatographi
nanofiltr
problem
blood
safeti
remain
despit
improv
viral
inactiv
method
plasmaderiv
product
could
alway
caus
infecti
concern
risk
contract
novel
pathogen
could
actual
detect
sustain
continu
emerg
new
agent
new
strain
exist
agent
potenti
threat
limit
virus
includ
bacteri
protozoan
prion
agent
among
agent
includ
hiv
hepat
virus
identifi
highestprior
agent
blood
safeti
intervent
consid
tabl
recombin
fviii
concentr
provid
improv
safeti
patient
hemophilia
significantli
reduc
risk
transmiss
bloodborn
infect
nevertheless
humanor
animalderiv
plasma
protein
still
includ
step
prepar
first
second
gener
rfviii
product
therebi
introduc
potenti
transmiss
human
anim
pathogen
two
exampl
briefli
treat
parvoviru
small
nonenvelop
viru
typic
caus
benign
flulik
ill
occur
frequent
childhood
viru
resist
current
viral
inactiv
step
use
manufactur
antihemophil
factor
concentr
transmiss
product
document
also
nucleic
acid
test
nat
screen
plasma
pool
implement
children
expos
plasmaderiv
product
time
like
antibodi
compar
unexpos
blood
product
one
first
gener
recombin
fviii
product
contain
human
serum
albumin
ad
stabil
rfviii
lyophil
associ
reliabl
seroconvers
parvoviru
even
though
studi
conduct
center
diseas
control
prevent
atlanta
limit
detect
serumconvers
poor
reliabl
plasma
minipool
screen
nat
reveal
albumin
also
sourc
tt
viru
found
first
gener
rfviii
concentr
prion
selfrepl
infecti
protein
caus
current
untreat
fatal
neurodegen
disord
vcjd
human
form
bovin
spongiform
encephalopathi
prionassoci
diseas
lengthi
incub
period
yr
unexpectedli
high
transmiss
rate
transfus
bse
scrapi
togeth
short
consist
incub
period
clinic
posit
recipi
experiment
demonstr
suggest
infect
titer
blood
substanti
blood
transfus
possibl
vehicl
transmiss
recent
demonstr
abnorm
prion
protein
spleen
sampl
postmortem
examin
unit
kingdom
elderli
hemophilia
patient
receiv
coagul
factor
concentr
obtain
pool
donor
includ
subject
incub
vcjd
subsequ
die
vcjd
outcom
recent
publish
survey
conduct
unit
kingdom
establish
preval
subclin
infect
prion
normal
popul
show
archiv
appendix
sampl
posit
abnorm
prion
protein
prp
preval
definit
trivial
take
account
size
plasma
pool
l
deriv
donor
fraction
produc
clot
factor
concentr
peripher
lymphoreticular
infect
seem
weak
barrier
crossspeci
transmiss
prion
note
challeng
make
infect
agent
elus
recognit
surveil
polici
mani
emerg
bloodborn
infecti
agent
character
longlast
silent
carrier
state
pathogen
present
circul
without
caus
notic
symptom
pathogen
highli
infecti
contain
blood
plasma
bloodborn
agent
common
transmiss
transfus
associ
clinic
appar
fatal
diseas
lack
effect
intervent
moreov
preval
subclin
diseas
known
well
challeng
deal
undefin
risk
requir
implement
surveil
risk
manag
measur
pathogen
bloodborn
stage
resist
viral
inactiv
step
manufactur
process
must
taken
particular
consider
potenti
threat
turoctocog
alfa
novel
advanc
categori
rfviii
produc
without
addit
human
anim
plasma
protein
develop
aim
provid
best
possibl
margin
safeti
hemophilia
patient
elimin
risk
bloodborn
infect
lifelong
therapi
turoctocog
alfa
purifi
seri
step
includ
immunoaffin
chromatographi
process
util
recombin
monoclon
antibodi
produc
cell
grown
plasmafre
environ
case
turoctocog
alfa
never
expos
plasma
risk
transmit
known
emerg
bloodborn
pathogen
virtual
elimin
advanc
techniqu
purif
util
product
turoctocog
alfa
result
final
product
formul
devoid
albumin
anim
humanderiv
materi
total
five
step
employ
remov
host
cell
medium
compon
chemic
use
purif
dna
protein
key
purif
step
use
nonanimalderiv
affin
ligand
produc
cho
cell
line
use
turoctocog
alfa
specif
fviii
manufactur
process
use
purifi
turoctocog
alfa
includ
two
addit
step
minimum
regulatori
requir
depict
tabl
solventdeterg
sd
treatment
standard
well
document
process
term
spectrum
potenti
pathogen
reduct
addit
inactiv
potenti
viral
contamin
sd
process
necessari
product
concentr
sd
treatment
turoctocog
alfa
conduct
respect
physicochemicalbiolog
characterist
rfviii
nevertheless
advers
reaction
final
prepar
possibl
techniqu
use
viral
inactiv
therefor
addit
practic
step
chromatographi
requir
remov
solventdeterg
residu
chemic
metabolit
immunoaffin
chromatographi
process
isol
full
molecul
rfviii
intact
heavi
chain
chromatograph
process
use
recombin
version
monoclon
antibodi
direct
integr
domain
heavi
chain
must
includ
residu
amino
acid
sequenc
step
exclud
incomplet
molecul
particularli
damag
heavi
chain
weak
point
posit
easili
inactiv
proteolysi
recombin
monoclon
antibodi
direct
domain
produc
cell
line
use
product
turoctocog
alfa
manufactur
realiz
avoid
contact
anim
addit
affin
step
highli
specif
fviii
shown
reliabl
remov
essenti
host
cell
protein
ionexchang
chromatographi
remov
impur
gener
produc
cell
line
use
electr
charg
elimin
impur
thu
obtain
purif
step
product
resin
use
mix
mode
captur
chromatographi
step
also
bind
fviii
multipl
interact
provid
addit
tool
remov
impur
research
optim
paramet
chromatograph
process
obtain
highli
purifi
rfviii
concentr
best
support
matrix
ion
exchang
select
obtain
highest
purifi
product
investig
contamin
protein
found
detect
limit
data
file
person
commun
nanofiltr
nm
pore
size
filter
design
remov
almost
virus
includ
protein
envelop
virus
like
parvoviru
nanofiltr
increas
clearanc
capac
virus
via
membranebas
ultrafiltr
system
implement
assur
high
viru
safeti
level
especi
nonenvelop
virus
thu
complement
profil
viral
reduct
treatment
activ
envelop
virus
sd
process
nonenvelop
virus
resist
sd
treatment
small
remov
filter
larger
mn
nanofiltr
consist
filter
protein
solut
membran
small
pore
size
condit
retain
virus
mechan
base
size
exclus
potenti
case
envelop
virus
present
would
inactiv
chemic
disrupt
surround
lipid
membran
immunoaffin
purif
mab
chromatographi
purif
step
remov
host
cell
protein
use
nonanim
deriv
fviii
monoclon
antibodi
charg
purif
ionexchang
chromatographi
rfviii
product
concentr
purifi
use
charg
chromatograph
resin
viru
remov
nanofiltr
nm
pore
pore
size
nm
capabl
captur
pathogen
base
size
includ
theoret
present
small
nonenvelop
virus
eg
parvovirus
disrupt
envelop
virus
prion
etc
size
exclus
rfviii
formul
without
aggregateagglutin
protein
turoctocog
alfa
purifi
use
pore
size
filter
nanofiltr
size
tight
enough
remov
smallest
virus
correspond
parvoviru
shown
model
viru
clearanc
valid
method
effici
remov
nm
filter
techniqu
refin
led
improv
viral
remov
establish
largescal
world
wide
experi
purif
process
rfviii
product
prion
remov
capac
log
log
demonstr
immunoaffin
step
result
total
clearanc
log
also
nanofiltr
may
remov
prion
provid
possibl
safeguard
new
infecti
agent
potenti
enter
human
plasma
pool
lastli
technolog
membran
nanofiltr
process
major
advantag
proteinviru
separ
also
protein
purif
recov
protein
activ
absenc
denatur
effect
gel
filtrat
step
provid
pure
protein
turoctocog
alfa
elimin
aggregatedagglutin
form
protein
high
capac
gel
filtrat
system
develop
purpos
isol
rfviii
high
yield
implement
gel
filtrat
rfviiicontain
fraction
collect
contain
exclus
fviii
filtrat
use
monitor
bioactiv
puriti
chromatograph
product
summari
two
dedic
viru
clearanc
step
sd
treatment
nanofiltr
pore
size
filter
includ
ensur
inactivationremov
potenti
present
envelop
nonenvelop
virus
inde
purif
process
turoctocog
alfa
nanofiltr
immunoaffin
step
contribut
prion
reduct
well
recombin
fviii
product
classifi
three
gener
base
degre
elimin
plasma
albumin
product
andor
formul
step
first
gener
product
use
plasma
andor
albumin
cell
cultur
process
final
formul
step
second
gener
product
use
serum
protein
cell
cultur
process
plasmafre
recombin
protein
classifi
third
gener
product
mani
physician
organ
commonwealth
develop
countri
denmark
canada
japan
encourag
switch
recombin
product
standard
treatment
hemophilia
fda
ema
prompt
drug
devic
manufactur
find
altern
use
human
anim
raw
materi
addit
whenev
possibl
togeth
viral
safeti
main
concern
develop
turoctocog
alfa
attempt
reduc
format
inhibitor
fviii
primari
object
two
guardian
tm
phase
studi
therefor
evalu
safeti
turoctocog
alfa
term
incid
inhibitor
adult
patient
n
expos
turoctocog
alfa
mean
rang
exposur
day
young
patient
n
mean
exposur
day
rang
patient
develop
inhibitor
trial
one
adult
patient
exclud
analysi
pretrialposit
inhibitor
test
interestingli
patient
receiv
dose
turoctocog
alfa
occurr
inhibitor
phase
studi
observ
patient
immedi
first
dose
turoctocog
alfa
show
sign
earli
inhibitor
develop
instanc
inhibitor
format
report
period
administr
singl
dose
turoctocog
alfa
iukg
regard
advers
event
infect
inhibitor
develop
guardian
tm
studi
six
nonseri
event
hypertens
sinu
tachycardia
insomnia
patient
increas
hepat
enzym
patient
contus
incorrect
dose
administr
one
pediatr
patient
evalu
possibl
probabl
relat
turoctocog
alfa
investig
overal
treatment
turoctocog
alfa
safe
none
infecti
concern
sever
new
bioengin
technolog
appli
fviii
improv
qualiti
treatment
hemophilia
patient
exampl
varieti
approach
evalu
increas
halflif
fviii
thu
reduc
administr
frequenc
addit
polyethylen
glycol
peg
fusion
protein
technolog
advanc
preclin
clinic
develop
structur
turoctocog
alfa
protein
similar
nativ
fviii
incorpor
glycopegyl
fviii
increas
plasma
halflif
fviii
inde
novel
sitespecif
pegyl
attach
peg
uniqu
oglycan
activ
thrombin
residu
part
bdomain
contain
pegyl
cleav
gener
activ
fviiia
similar
structur
nativ
fviiia
pharmacokinet
paramet
estim
differ
anim
model
hemophilia
dog
mice
rabbit
monkey
nearli
twofold
prolong
halflif
demonstr
phase
clinic
trial
demonstr
signific
increas
plasma
halflif
twentysix
patient
receiv
one
dose
previou
fviii
product
follow
singl
dose
mean
termin
halflif
h
rang
longer
patient
previou
product
estim
time
dose
u
kg
plasma
activ
rang
singl
dose
ukg
well
toler
patient
hemophilia
safeti
concern
taken
togeth
clinic
data
show
turoctocog
alfa
serv
optim
tool
longact
futur
fviii
product
rational
produc
rfviii
ultim
reduct
immunogen
infecti
challeng
patient
turoctocog
alfa
manufactur
process
use
wellknown
mammalian
cell
line
suitabl
rfviii
product
entir
free
ad
animalor
humanderiv
addit
design
develop
three
complementari
approach
use
minim
risk
potenti
contamin
thorough
test
cell
line
close
control
medium
capac
purif
process
elimin
potenti
contamin
systemat
analysi
final
product
safeti
data
obtain
date
demonstr
turoctocog
alfa
safe
use
clinic
practic
manufactur
process
set
new
standard
term
puriti
pathogen
safeti
author
declar
serv
consult
novo
nordisk
csl
behr
pfizer
receiv
grant
research
baxter
bayer
